Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-002 versus mycophenolate mofetil in AQP4-IgG positive NMOSD
CTR20243045Phase 3Active
- Sponsor
- ImmunoCare
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by ImmunoCare. Started Dec 2024; status: active.
02
Drugs
IMC-002
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20243045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243045.